Novo Nordisk's third quarter sales were DKK 587.3 billion, with an expected DKK 578 billion. Novo Nordisk's third quarter sales were DKK 587.3 billion, with an expected DKK 578 billion. In the third quarter, sales of Wegovy, a weight loss miracle drug, reached DKK 9.65 billion, with an expected DKK 8.07 billion. The third quarter's pre tax profit was DKK 280.6 billion, with an expected profit of DKK 266.8 billion. The EBIT for the third quarter was DKK 269.1 billion, with an expected level of DKK 254.2 billion. The net income for the third quarter was DKK 224.8 billion, with an expected DKK 214.9 billion.